Voleon Capital Management
NVCR icon

Voleon Capital Management’s NovoCure NVCR Stock Holding History

Voleon Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,761
Closed -$514K – 872
2025
Q4 		$514K Buy
39,761
+21,914
+123% +$281K 0.01% 567
2025
Q3 		$231K Buy
+17,847
New +$238K 0.01% 798

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Voleon Capital Management's NVCR Position: Q1 2026 in Review

Voleon Capital Management sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 39,761 shares — an estimated $514K sold.

Voleon Capital Management first reported a position in NVCR in Q3 2025 and held it in 2 quarters. The position peaked at $514K in Q4 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Voleon Capital Management reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Voleon Capital Management sold 39,761 NovoCure shares in Q1 2026, an estimated $514K.
  • Voleon Capital Management first reported a position in NovoCure in Q3 2025 and held it in 2 quarters.
  • Voleon Capital Management's NovoCure position peaked at $514K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.